RSS   Newsletter   Contact   Advertise with us
Post Online Media
Expanding   A translational immuno-oncology hub

Eli Lilly to expand in New York, create 50 jobs

Eli LillyEli Lilly & Co. announced plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York, New York.

Upon completion in 2016, this space will include a translational immuno-oncology hub and a Lilly "portal," which will provide local academic scientists with opportunities for collaborative access to cutting-edge drug discovery capabilities, including chemistry and lead optimization expertise.

READ MORE VTS to create 200 jobs, invest $2.25 million in New York City

The expansion will allow Lilly to strengthen its relationships with local academic institutions and prominent medical schools. Increased collaboration will help expedite the discovery and development of new medicines in Lilly's key therapeutic areas, including oncology, diabetes and related complications, neurodegeneration, immunology and pain.

This is Lilly's third strategic research and development expansion this year with a focus on internal and external collaborations. In May, Lilly announced it would build a delivery and device innovation center in Cambridge, Massachusetts. In July, Lilly announced an expansion of its biotechnology center in San Diego, California.

Lilly initially entered the New York and New Jersey area with the acquisition of ImClone in 2008. In 2010, Lilly opened its research and development site at the Alexandria Center for Life Science, which is located near the East River in New York.

Lilly also has a manufacturing and clinical development center in Bridgewater, New Jersey.




What to read next





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy